Akhil Hegde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akhil Hegde has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Abel Ang
1 shared publication- Alem W. Kahsai
Department of Medicine, Duke University Medical Center
1 shared publication - Eli Chan
Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
1 shared publication - Harm Maarsingh
Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
1 shared publication - Hyeje C. Sumajit
Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, Florida, USA
1 shared publication Jack Rivers
1 shared publication
Latest Publications
- Open Access
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models
Asthma is a chronic inflammatory disease associated with episodic airway narrowing. Inhaled β2-adrenergic receptor (β2AR) agonists (β2-agonists) promote — with limited efficacy — bronchodilation in asthma. All β2-agonists are canonical orthosteric ligands that bind the same site as endogenous epinephrine. We recently isolated a β2AR-selective positive allosteric modulator (PAM), compound-6 (Cmpd-6), which binds outside of the orthosteric site and modulates orthosteric ligand functions. With the emerging therapeutic potential of G-protein coupled receptor allosteric ligands, we investigated the impact of Cmpd-6 on β2AR-mediated bronchoprotection. Consistent with our findings using human β2ARs, Cmpd-6 allosterically potentiated β2-agonist binding to guinea pig β2ARs and downstream signaling of β2ARs. In contrast, Cmpd-6 had no such effect on murine β2ARs, which lack a crucial amino acid in the Cmpd-6 allosteric binding site. Importantly, Cmpd-6 enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in guinea pig lung slices, but — in line with the binding studies — not in mice. Moreover, Cmpd-6 robustly potentiated β2 agonist–mediated bronchoprotection against allergen-induced airway constriction in lung slices obtained from a guinea pig model of allergic asthma. Cmpd-6 similarly enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in human lung slices. Our results highlight the potential of β2AR-selective PAMs in the treatment of airway narrowing in asthma and other obstructive respiratory diseases.
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Open AccessAllosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models
Asthma is a chronic inflammatory disease associated with episodic airway narrowing. Inhaled β2-adrenergic receptor (β2AR) agonists (β2-agonists) promote — with limited efficacy — bronchodilation in asthma. All β2-agonists are canonical orthosteric ligands that bind the same site as endogenous epinephrine. We recently isolated a β2AR-selective positive allosteric modulator (PAM), compound-6 (Cmpd-6), which binds outside of the orthosteric site and modulates orthosteric ligand functions. With the emerging therapeutic potential of G-protein coupled receptor allosteric ligands, we investigated the impact of Cmpd-6 on β2AR-mediated bronchoprotection. Consistent with our findings using human β2ARs, Cmpd-6 allosterically potentiated β2-agonist binding to guinea pig β2ARs and downstream signaling of β2ARs. In contrast, Cmpd-6 had no such effect on murine β2ARs, which lack a crucial amino acid in the Cmpd-6 allosteric binding site. Importantly, Cmpd-6 enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in guinea pig lung slices, but — in line with the binding studies — not in mice. Moreover, Cmpd-6 robustly potentiated β2 agonist–mediated bronchoprotection against allergen-induced airway constriction in lung slices obtained from a guinea pig model of allergic asthma. Cmpd-6 similarly enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in human lung slices. Our results highlight the potential of β2AR-selective PAMs in the treatment of airway narrowing in asthma and other obstructive respiratory diseases.
- 1 May 2013
- Published by Elsevier in Pancreatology
- Vol. 13 (3)
Effect of cystathionine-gamma-lyase gene deletion in caerulein-induced acute pancreatitis in the mouse
- 1 May 2013
- Published by Elsevier in Pancreatology
- Vol. 13 (3)
Effect of cystathionine-gamma-lyase gene deletion in caerulein-induced acute pancreatitis in the mouse
- 1 April 2011
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 10 (2) , 118-122
Hydrogen Sulfide in Inflammation: Friend or Foe?
Hydrogen sulfide (H2S), the gaseous mediator produced by various cells in our body, was recently discovered to play a major role in human physiology despite its toxic nature known for centuries. In addition to its pathophysiological relevance in cardiovascular and neuronal disorders, there is considerable interest in the significance of H2S in inflammation. A number of preclinical studies in our laboratory as well as by others, using H2S donors and inhibitors of its endogenous synthesis, have provided evidence for both pro- and anti-inflammatory character of H2S. But so far, there is a significant lack of support from relevant clinical studies. One of the major contentious issues being variable dose and sampling time, controversies exist on the precise friend or foe nature of this gaseous transmitter. However, it is well accepted that once a clearer picture of the whole story of H2S in inflammation emerges, potential for therapeutic manipulations in this field are immense. This review focuses on the intriguing effects of H2S in some of the inflammatory conditions such as acute pancreatitis, sepsis, burn injuries and local inflammation of the joints. Active research projects have been undertaken to elucidate the mechanisms of action of H2S in inflammation, including neurogenic inflammation and interaction with other biological mediators and pathways. The early and fragmentary evidence obtained holds promise for a successful drug intervention for these inflammatory diseases.
- 1 April 2011
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 10 (2) , 118-122
Hydrogen Sulfide in Inflammation: Friend or Foe?
Hydrogen sulfide (H2S), the gaseous mediator produced by various cells in our body, was recently discovered to play a major role in human physiology despite its toxic nature known for centuries. In addition to its pathophysiological relevance in cardiovascular and neuronal disorders, there is considerable interest in the significance of H2S in inflammation. A number of preclinical studies in our laboratory as well as by others, using H2S donors and inhibitors of its endogenous synthesis, have provided evidence for both pro- and anti-inflammatory character of H2S. But so far, there is a significant lack of support from relevant clinical studies. One of the major contentious issues being variable dose and sampling time, controversies exist on the precise friend or foe nature of this gaseous transmitter. However, it is well accepted that once a clearer picture of the whole story of H2S in inflammation emerges, potential for therapeutic manipulations in this field are immense. This review focuses on the intriguing effects of H2S in some of the inflammatory conditions such as acute pancreatitis, sepsis, burn injuries and local inflammation of the joints. Active research projects have been undertaken to elucidate the mechanisms of action of H2S in inflammation, including neurogenic inflammation and interaction with other biological mediators and pathways. The early and fragmentary evidence obtained holds promise for a successful drug intervention for these inflammatory diseases.
- 1 April 2009
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 61 (4) , 451-458
Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats
Objectives The effects of the flavonoid rutin on the anticoagulant activity of oral warfarin and the protein binding and pharmacokinetics of its enantiomers were investigated in rats. Methods A single dose of racemic warfarin, 1.5 mg/kg, was administered orally to rats either alone or oil day 5 of ail 8-day oral regimen of rutin, 1 g/kg daily. Results Rutin reduced the anticoagulant effect of racemic warfarin, evident as a 31% reduction in the area under the prothrombin complex activty-time curve (P < 0.05). Key findings Rutin had no apparent effect on pre-treatment baseline blood coagulation. It enhanced the in-vitro serum protein binding of S- and R-warfarin (reflected by 40% and 26% reductions in unbound fraction, respectively), and thus restricted distribution by 33 and 21%, respectively. Treatment with rutin significantly decreased the elimination half-life of S-warfarin by 37% as a result of the 69% increase ill unbound clearance of the S-enantiomer. This effect was attributed to a significant 77% increase in the unbound fort-nation clearance of the overall oxidative and reductive metabolites, and an increase in the unbound renal clearance of the more potent S-enantiomer of warfarin. Conclusions Concurrent rutin administration is likely to reduce the anticoagulant effect of racemic warfarin, reflecting a significant decrease in the elimination half-life of the more potent S-enantiomer.
- 1 April 2009
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 61 (4) , 451-458
Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats
Objectives The effects of the flavonoid rutin on the anticoagulant activity of oral warfarin and the protein binding and pharmacokinetics of its enantiomers were investigated in rats. Methods A single dose of racemic warfarin, 1.5 mg/kg, was administered orally to rats either alone or oil day 5 of ail 8-day oral regimen of rutin, 1 g/kg daily. Results Rutin reduced the anticoagulant effect of racemic warfarin, evident as a 31% reduction in the area under the prothrombin complex activty-time curve (P < 0.05). Key findings Rutin had no apparent effect on pre-treatment baseline blood coagulation. It enhanced the in-vitro serum protein binding of S- and R-warfarin (reflected by 40% and 26% reductions in unbound fraction, respectively), and thus restricted distribution by 33 and 21%, respectively. Treatment with rutin significantly decreased the elimination half-life of S-warfarin by 37% as a result of the 69% increase ill unbound clearance of the S-enantiomer. This effect was attributed to a significant 77% increase in the unbound fort-nation clearance of the overall oxidative and reductive metabolites, and an increase in the unbound renal clearance of the more potent S-enantiomer of warfarin. Conclusions Concurrent rutin administration is likely to reduce the anticoagulant effect of racemic warfarin, reflecting a significant decrease in the elimination half-life of the more potent S-enantiomer.
- Open Access
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 918.5
Neurokinin‐1 Receptor antagonist treatment alleviates CLP‐induced polymicrobial sepsis in mice, acting via NFkappaB
We have earlier shown a beneficial effect of substance P (SP) receptor blocking on lung inflammation in sepsis by using SP receptor antagonist SR140333. To further understand the mechanism, we evaluated the effect of SR140333 on plasma SP levels and lung nuclear transcription factor NFκB in sepsis. Sepsis was induced in male Swiss mice by cecal ligation and puncture (CLP). Sham operated animals received the same surgical procedure except cecal ligation and puncture. Vehicle or SR140333 (1 mg/kg; s.c.) was administered to CLP mice either 30 min before or 1 h after the CLP. 8 h after surgery, plasma SP levels were estimated and lung tissue was analyzed for binding activity of NFκB. CLP induced sepsis resulted in a significant increase in plasma SP levels in vehicle treated mice compared to the corresponding levels in sham mice. Prophylactic and therapeutic administration of SR140333 showed a significant reduction in plasma SP levels. NFκB is known to be responsible for the gene regulation of various mediators in lung inflammation. We observed a significant increase in the binding activity of NFκB in lung in CLP operated mice. SR140333 treatment lowered the binding activity of NFκB indicating a role for this transcription factor downstream of SP in inducing lung inflammation. These results show that SR140333 therapy may be beneficial in the treatment of lung inflammation in sepsis by acting via NFκB. Hegde A et al J Leukoc Biol 2007, 82:678–85.
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 918.5
Open AccessNeurokinin‐1 Receptor antagonist treatment alleviates CLP‐induced polymicrobial sepsis in mice, acting via NFkappaB
We have earlier shown a beneficial effect of substance P (SP) receptor blocking on lung inflammation in sepsis by using SP receptor antagonist SR140333. To further understand the mechanism, we evaluated the effect of SR140333 on plasma SP levels and lung nuclear transcription factor NFκB in sepsis. Sepsis was induced in male Swiss mice by cecal ligation and puncture (CLP). Sham operated animals received the same surgical procedure except cecal ligation and puncture. Vehicle or SR140333 (1 mg/kg; s.c.) was administered to CLP mice either 30 min before or 1 h after the CLP. 8 h after surgery, plasma SP levels were estimated and lung tissue was analyzed for binding activity of NFκB. CLP induced sepsis resulted in a significant increase in plasma SP levels in vehicle treated mice compared to the corresponding levels in sham mice. Prophylactic and therapeutic administration of SR140333 showed a significant reduction in plasma SP levels. NFκB is known to be responsible for the gene regulation of various mediators in lung inflammation. We observed a significant increase in the binding activity of NFκB in lung in CLP operated mice. SR140333 treatment lowered the binding activity of NFκB indicating a role for this transcription factor downstream of SP in inducing lung inflammation. These results show that SR140333 therapy may be beneficial in the treatment of lung inflammation in sepsis by acting via NFκB. Hegde A et al J Leukoc Biol 2007, 82:678–85.